COVID-19. COVID-19
Conditions
Interventions
Intervention 1: Intervention group: The intervention group will receive 8 mg bromhexine tablets every 8 hours for 14 days. Intervention 2: Control group: will receive 3 placebo tablets per day for 14
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 18 years and older, both sexes Having home contact, unmasked contact with a patient with Covid-19 confirmed by RT-PCR or clinical evidence or radiography of pneumonia and acute respiratory distress syndrome (ARDS); No clinical signs of Covid-19 (fever, cough, dyspnea, shortness of breath, sore throat, extreme tiredness, digestive problems); No chronic respiratory problems or other illnesses that are mistaken for symptoms of COVID-19
Exclusion criteria
Exclusion criteria: Involvement with any other ongoing studies. Pregnant or breast feeding woman or with positive pregnancy test result for fetal safety Severe liver disease as a strong confounding factor Severe renal failure as a strong confounding factor Refusal by attending physician for no clinical equipoise Advanced active malignancy as a strong confounding factor Patient in other clinical trials for COVID-19 within 30 days before/after ICF as a confounding factor/s Other patient characteristics (not thought to be related to underlying COVID-19) that portend a very poor prognosis (e.g, severe liver failure, severe renal failure, and etc. May impact primary and other clinical endpoints- Known allergy to study drug or its ingredients related to renin-angiotensin system (RAS), or frequent and/or severe allergic reactions with multiple medications for patient protection purposes Other uncontrolled disease, as judged by investigators that may influence study endpoint and other clinical outcome
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Test for the presence or absence of nucleic acid in the corona virus. Timepoint: 15 days after the intervention. Method of measurement: real-time PCR.;Serum IgM and IgG levels. Timepoint: 15 days after the intervention. Method of measurement: Immunology test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactKhalil Ansarin
Tabriz University of Medical Sciences
Outcome results
None listed